Related references
Note: Only part of the references are listed.
Editorial Material
Psychology
Manoj L. Kumar et al.
INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE
(2023)
Retraction
Radiology, Nuclear Medicine & Medical Imaging
Lilan Fu et al.
EUROPEAN RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tevfik Fikret Cermik et al.
Summary: The role of Ga-68-DOTA-FAPI-04 PET/CT in imaging of primary, metastatic, and recurrent cancers was investigated in this study. The results showed that Ga-68-DOTA-FAPI-04 PET/CT has high sensitivity and accuracy in diagnosing and staging solid tumors. Furthermore, FAPI molecules are predicted to be used in radionuclide therapy for patients with metastatic disease unresponsive to other treatments.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bingxin Gu et al.
Summary: This study evaluated the diagnostic value of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT for recurrent soft tissue sarcoma (STS) and compared it with [F-18]FDG PET/CT. The results showed that [(68)Ga]Ga-DOTA-FAPI-04 PET/CT was more accurate than [F-18]FDG PET/CT in detecting recurrent lesions of liposarcoma, MSFT, and IDCS.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Patrick Conen et al.
Summary: In this retrospective study, the diagnostic value of three different radiotracers for the noninvasive prediction of kidney fibrosis was analyzed. The results showed a significant negative correlation between renal parenchymal [(68) Ga]Ga-FAPI uptake and glomerular filtration rate (GFR), highlighting the potential value of [(68) Ga]Ga-FAPI for the noninvasive evaluation of kidney fibrosis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Boqia Xie et al.
Summary: The aim of this study was to explore the correlation between F-18-labeled fibroblast activation protein inhibitor (FAPI) and cardiovascular magnetic resonance (CMR) parameters in ST-elevation myocardial infarction (STEMI) patients, and investigate the value of FAPI imaging in predicting cardiac functional recovery. The study found that FAPI imaging can better detect involved myocardium in reperfused STEMI patients and is associated with myocardial damage and follow-up left ventricular ejection fraction (LVEF).
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yizhen Pang et al.
Summary: This study evaluated the diagnostic performance of [Ga-68]Ga-FAPI PET/CT in primary and metastatic pancreatic carcinoma lesions and found it to have higher sensitivity and accuracy in TNM staging compared to [F-18]FDG PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Mengting Li et al.
Summary: This article reviews the application of fibroblast activation protein (FAP) in nuclear medicine, highlighting the potential value of FAPI radiopharmaceuticals in tumor diagnosis and therapy. Despite limitations in current studies, further exploration of the clinical value of FAPI through better-designed and larger clinical trials in the future is likely to be worthwhile.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Youcai Li et al.
Summary: The study compared the primary staging of F-18 labeled fibroblast activation protein inhibitor ([F-18]F-FAPI) with that of F-18 labeled fluordesoxyglucose positron emission tomography/computed tomography ([F-18]F-FDG PET/CT) in patients with lung adenocarcinoma (LAD). The results showed that [F-18]F-FAPI PET/CT had a high detection rate for primary LAD and provided clearer tumor delineation and more lesions, especially in lymph nodes, the brain, and pleura. However, brain MRI could identify more and smaller lesions than [F-18]F-FAPI PET/CT.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cihan Gundogan et al.
Summary: This study evaluated the diagnostic sensitivities of Ga-68-FAPI-04 PET/CT and F-18-FDG PET/CT in GAc. The results showed that Ga-68-FAPI-04 PET/CT had higher sensitivity and specificity, which may help avoid invasive diagnostic procedures.
NUCLEAR MEDICINE COMMUNICATIONS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lijuan Wang et al.
Summary: Ga-68-FAPI PET/CT may outperform F-18-FDG PET/CT in evaluating lung cancer, particularly in the detection of metastasis to the brain, lymph nodes, bone, and pleura.
Article
Cardiac & Cardiovascular Systems
Susan Notohamiprodjo et al.
Summary: This study demonstrated the feasibility of noninvasive imaging of fibroblast activation protein (FAP) expression after myocardial infarction (MI) using Ga-68-FAPI-04-PET, and showed that Ga-68-FAPI-04 uptake extends beyond the actual infarcted area in the infarct territory. Follow-up CMR confirmed the overestimation of the infarct size by Ga-68-FAPI-04 uptake.
JOURNAL OF NUCLEAR CARDIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chunxia Qin et al.
Summary: The study evaluated the performance of Ga-68-FAPI PET/MR in diagnosing primary tumors and metastatic lesions in patients with gastric carcinomas, comparing it with F-18-FDG PET/CT. The results showed that Ga-68-FAPI PET/MR outperformed F-18-FDG PET/CT in detecting primary tumors and most metastatic lesions, suggesting its potential as a replacement for F-18-FDG PET/CT.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lukas Kessler et al.
Summary: The study found that novel radiolabeled FAP inhibitors showed high tumor uptake in bone and soft-tissue sarcoma patients, indicating potential applications for clinical diagnosis and treatment.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Yilin. Huang et al.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yun Chen et al.
Summary: This study aimed to assess the potential of Ga-68-DOTA-FAPI-04 PET/CT for detecting radioiodine-refractory differentiated thyroid cancer (RR-DTC) lesions. Analysis of clinical and imaging data of 24 RR-DTC patients showed that Ga-68-DOTA-FAPI-04 PET/CT had a promising detection rate for RR-DTC metastasis and could potentially serve as a therapeutic target for RR-DTC.
ANNALS OF NUCLEAR MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Dengsai Peng et al.
Summary: This article introduces the application of fibroblast activation protein inhibitor PET/CT in malignant tumors of the digestive system. This method can better display primary tumors, metastases, and lymph nodes, and provide new treatment methods.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jonathan Kuten et al.
Summary: In this pilot study, FAPI PET/CT outperformed FDG PET/CT in detecting primary gastric adenocarcinoma and peritoneal carcinomatosis from gastric cancer. FAPI PET/CT also showed promise for monitoring response to treatment in patients with peritoneal carcinomatosis from gastric cancer; however, larger trials are needed to validate these preliminary findings.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Donglang Jiang et al.
Summary: [(68) Ga]Ga-FAPI-04 PET showed a superior detection rate for primary gastric cancer compared to [F-18]-FDG PET. It provided better performance in the diagnosis and staging of gastric cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lianjun Lan et al.
Summary: The study aimed to compare the detection performance of [(68) Ga]Ga-DOTA-FAPI-04 and [F-18]FDG PET/CT in patients with various oncological and non-oncological lesions. [(68) Ga]Ga-DOTA-FAPI-04 PET/CT showed significantly higher uptake and detection rate for primary, nodal, and distant metastatic lesions of solid tumors compared to [F-18]FDG PET/CT. Except for myeloma and lymphoma, [(68) Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated superior detection efficacy for various primary and metastatic lesions than [F-18]FDG PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Tingting Xu et al.
Summary: Our case demonstrated that Ga-68-DOTA-FAPI-04 is not superior to F-18-FDG in the imaging of cardiac angiosarcoma, but it is still possible to produce beneficial value in the evaluation of the involvement of the lesion.
CLINICAL NUCLEAR MEDICINE
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Aisheng Dong et al.
Summary: This study describes the findings of FAPI PET/CT in renal tumors, including a case of lipid-poor renal angiomyolipoma and a case of high-grade clear cell renal cell carcinoma. Both tumors showed intense FAPI uptake, indicating that lipid-poor renal angiomyolipoma should be considered in the differential diagnosis of FAPI-avid renal tumors.
CLINICAL NUCLEAR MEDICINE
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hao Fu et al.
CLINICAL NUCLEAR MEDICINE
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Hessamoddin Roustaei et al.
Summary: This article reviews the clinical studies using FAP-specific radioligands as novel theranostic agents in both oncologic and nononcologic indications. The studies observed high affinity of these radioligands to primary sites of various malignant tumors, and they outperformed traditional F-18-FDG PET/CT in certain aspects. Further research is needed on the role of FAPI radioligands in oncologic imaging, radionuclide therapy, and radiotherapy treatment planning.
CONTRAST MEDIA & MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xin Zhou et al.
Summary: This study compared the clinical staging performance of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT and 2-[F-18]FDG PET/CT in non-small cell lung cancer (NSCLC) patients. The results showed that [(68) Ga]Ga-DOTA-FAPI-04 PET/CT had better staging performance in NSCLC patients, especially in localized disease.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Halil Komek et al.
Summary: [(68) Ga]Ga-DOTA-FAPI-04 PET/CT demonstrates higher sensitivity and specificity in the evaluation of primary lesions and metastases in patients with colorectal cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rong Lin et al.
Summary: This study compared the performance of [Ga-68]Ga-DOTA-FAPI-04 and [F-18]FDG PET/CT in evaluating gastric cancer. The results showed that [Ga-68]Ga-DOTA-FAPI-04 PET/CT outperformed [F-18]FDG PET/CT in detecting peritoneal, abdominal lymph node, and bone metastases. Additionally, [Ga-68]Ga-DOTA-FAPI-04 PET/CT provided more valuable information for patients with recurrent disease and had the potential in monitoring treatment response.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Tingting Yuan et al.
JOURNAL OF NUCLEAR CARDIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Manuel Roehrich et al.
Summary: This study aimed to evaluate the imaging properties of static and dynamic fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT in various types of fibrosing interstitial lung diseases (fILDs) and lung cancer (LC). The results showed that Ga-68-FAPI PET/CT imaging had high uptake and good imaging characteristics for fILD and LC.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Richard P. Baum et al.
Summary: The study on Lu-177-FAP-2286 for peptide-targeted radionuclide therapy (PTRT) showed promising results in advanced adenocarcinoma patients, with a relatively good tolerability and acceptable side effects. Further prospective clinical studies are needed to confirm its efficacy.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Justin Ferdinandus et al.
Summary: This study investigates the feasibility and safety of Y-90-FAPI-46 radioligand therapy in patients with solid tumors. The results demonstrate good tolerability and a low rate of adverse events. Furthermore, the low radiation doses to at-risk organs suggest the possibility of repeat cycles of Y-90-FAPI-46.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Katrin S. Roth et al.
Summary: Imaging studies using PET tracers acting as fibroblast activation protein inhibitors (FAPIs) show promising results in cancer imaging and may have superior sensitivity compared to [F-18]-FDG PET/CT alone.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Torsten Kuwert et al.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Johanna Diekmann et al.
Summary: After AMI, the upregulation of FAP exceeds the infarct region, and FAP volume is correlated with CMR parameters but weakly correlated with LV ejection fraction. FAP-targeted imaging may serve as a biomarker for LV remodeling.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Umut Elboga et al.
Summary: Ga-68-FAPI PET/CT was found to be superior to (18)FDG PET/CT in detecting peritoneal involvement and assessing primary tumors and other metastatic foci, providing high image quality and localization ability.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Dheeratama Siripongsatian et al.
Summary: [(68)Ga]Ga-FAPI PET/CT with dedicated liver PET/MRI shows potential for superior detection of hepatic malignancy compared with [F-18]FDG PET/CT or MRI alone. The combination of [(68)Ga]Ga-FAPI PET/CT and dedicated liver PET/MRI provides higher sensitivity and better activity in detecting liver malignancies, which has significant clinical implications.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Rheumatology
Daphne N. Dorst et al.
Summary: This study demonstrates the feasibility of selective FAP-tPDT in rheumatoid arthritis synovium ex vivo. Additionally, it provides the first indication that FAP-targeted PET/CT can be used to image arthritic joints, an important step towards the application of FAP-tPDT as a targeted locoregional therapy for RA.
Article
Radiology, Nuclear Medicine & Medical Imaging
Shaoming Chen et al.
Summary: This study evaluated the potential value of [Ga-68]Ga-labelled fibroblast activation protein inhibitor ([Ga-68]Ga-FAPI) positron emission tomography/computed tomography (PET/CT) in preoperative staging for oral squamous cell carcinoma (OSCC) patients. The results showed that [Ga-68]Ga-FAPI PET/CT had similar accuracy in detecting primary lesions compared to 2-[F-18]fluoro-2-deoxy-D-glucose (2-[F-18]FDG) PET/CT, but it had higher specificity and accuracy in evaluating neck lymph node metastases.
EUROPEAN RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ximin Shi et al.
Summary: The study evaluated the diagnostic performance of Ga-68-FAPI-04 PET in detecting and characterizing hepatic nodules, showing high sensitivity in detecting hepatic malignancies.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Haojun Chen et al.
Summary: This prospective study evaluated the potential usefulness of [Ga-68]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) in oncological evaluation of patients with inconclusive [F-18]FDG PET/CT findings. The study found that [Ga-68]Ga-DOTA-FAPI-04 may have a complementary role in discriminating mass lesions on conventional imaging, locating unknown primary sites in biopsy-proven metastatic malignancy, modifying tumor staging, and detecting suspected disease recurrence. However, caution should be exercised when interpreting [Ga-68]Ga-DOTA-FAPI-04 PET/CT images in tumors complicated with inflammation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Chunlei Fan et al.
Summary: The study compared Ga-68-FAPI and F-18-FDG PET/CT in a patient with GSRCC and found that Ga-68-FAPI PET/CT demonstrated superior tumor-to-background contrast and detected more metastatic lesions than F-18-FDG PET/CT. This case highlights the better performance of Ga-68-FAPI PET/CT in identifying both primary and metastatic lesions in GSRCC compared to F-18-FDG PET/CT.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ximin Shi et al.
Summary: This study compared the performance of Ga-68-labelled fibroblast activating protein inhibitor (FAPI) PET and F-18-FDG PET for imaging of hepatic tumours, finding that Ga-68-FAPI PET-CT has superior potential in the detection of primary hepatic malignancy compared to F-18-FDG.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
J. Siebermair et al.
Summary: This study investigated myocardial FAPI uptake in patients undergoing Ga-68 FAPI PET. Results showed an association between myocardial tracer accumulation and coronary artery disease, age, and left ventricular ejection fraction. Further research is needed to evaluate the reliability of measuring fibroblast activation and its potential use for risk stratification in CAD and left ventricular remodeling.
JOURNAL OF NUCLEAR CARDIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Manuel Roehrich et al.
Summary: The use of Ga-68-FAPI PET/CT imaging in PDAC patients led to significant changes in TNM staging and impacted the management of some patients.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Yizhen Pang et al.
Summary: This case report demonstrated the use of Ga-68-fibroblast activation protein inhibitor PET/CT in detecting chromophobe renal cell carcinoma, which showed promising results compared to F-18-FDG PET/CT in identifying the primary tumor in a patient with bone metastasis.
CLINICAL NUCLEAR MEDICINE
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Wenhui Fu et al.
Summary: A 51-year-old woman newly diagnosed with lung cancer experienced progressive left hip pain for 1 month. Imaging revealed multiple hypermetabolic lesions throughout the body, with a suspicious lesion in the brain eventually confirmed as brain metastasis through MRI.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Punit Sharma et al.
Summary: FAP inhibitor PET/CT shows promising potential as a molecular imaging tool in oncology, with superior performance in certain types of cancers compared to F-18-FDG PET/CT. Its potential as a theranostic tool also merits attention, although further research and trials are needed to validate its effectiveness.
CLINICAL NUCLEAR MEDICINE
(2021)
Editorial Material
Cardiac & Cardiovascular Systems
Liang Zhao et al.
EUROPEAN HEART JOURNAL
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Liang Zhao et al.
Summary: This study aimed to explore the efficacy of [Ga-68]Ga-DOTA-FAPI-04 PET/CT compared to F-18-FDG PET/CT in evaluating peritoneal carcinomatosis in cancer patients. The results showed that [Ga-68]Ga-DOTA-FAPI-04 PET/CT had higher sensitivity, particularly in patients with gastric cancer, and provided better detection of peritoneal lesions compared to F-18-FDG PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Biochemistry & Molecular Biology
Giorgio Treglia et al.
Summary: Recent studies have compared radiolabeled fibroblast activation protein inhibitors (FAPI) and fluorine-18 fluorodeoxyglucose ([F-18]F-FDG) as PET radiotracers in oncology. The evidence suggests that radiolabeled FAPI PET generally shows equal or higher detection rates for primary tumors and metastatic lesions compared to [F-18]F-FDG PET, particularly in gastrointestinal tumors, liver tumors, breast cancer, and nasopharyngeal carcinoma. Further comparison studies are needed to determine the optimal application of radiolabeled FAPI PET.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chunxia Qin et al.
Summary: This study compared the diagnostic ability of Ga-68-FAPI and F-18-FDG PET/MR in NPC patients, finding that Ga-68-FAPI outperformed F-18-FDG in delineating the primary tumor and detecting suspected distant metastases. The research suggests that Ga-68-FAPI hybrid PET/MR may serve as a single-step staging modality for NPC patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yizhen Pang et al.
Summary: This study compared the diagnostic efficacy of Ga-68-FAPI PET/CT and F-18-FDG PET/CT in gastrointestinal malignancies, showing that Ga-68-FAPI PET/CT outperformed in detecting primary and metastatic lesions, with higher sensitivity.
Article
Radiology, Nuclear Medicine & Medical Imaging
Halil Komek et al.
Summary: The study demonstrates that (68)Ga-FAPI-04 PET/CT is superior to F-18-FDG PET/CT in detecting primary tumors in breast cancer patients with its high sensitivity, high SUVmax, and high TBR. Additionally, (68)Ga-FAPI-04 PET/CT is also superior in detecting lymph node, hepatic, bone, and cerebral metastases due to its lower background activity and higher uptake in subcentimetric lesions.
ANNALS OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Clemens Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Liang Zhao et al.
Summary: The study demonstrated the clinical utility of [Ga-68]Ga-FAPI PET/CT in primary staging and recurrence detection in nasopharyngeal carcinoma, showing potential for improved diagnostic accuracy and imaging evaluation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Oncology
Serkan Kuyumcu et al.
Summary: FAP, overexpressed on CAFs, is a promising target for molecular imaging of various tumors. Small-molecule FAP inhibitors radiolabeled with Ga-68 have shown potential to compete with (18)FDG in cancer imaging. Theranostic properties of FAP may aid in the treatment of refractory cancers.
FRONTIERS IN ONCOLOGY
(2021)
Review
Chemistry, Medicinal
Surachet Imlimthan et al.
Summary: The tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy in the past decade, with cancer-associated fibroblasts (CAFs) being identified as critical stromal cells that regulate tumor growth and progression. Research on FAP-based radiopharmaceuticals for visualizing malignancies and delivering theranostic radiopharmaceuticals to the TME has been intensively investigated. This review provides an overview of TME compositions, particularly CAFs and FAP, and their roles in cancer biology, as well as the challenges and requirements for radiolabeled FAP inhibitors in clinical translation.
Article
Radiology, Nuclear Medicine & Medical Imaging
Umut Elboga et al.
Summary: In this study, Ga-68-FAPI PET/CT was found to be superior to (18)FDG PET/CT in detecting more lesions in breast cancer patients. Additionally, Ga-68-FAPI PET/CT was able to lead to a change in treatment approach for patients with newly detected lesions in the post-chemotherapy group.
ANNALS OF NUCLEAR MEDICINE
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Martina Sollini et al.
Summary: Fibroblast activation protein-alpha (FAP alpha) is a promising target for therapeutic and molecular imaging applications due to its overexpression on cancer-associated fibroblasts in most epithelial neoplasms. [68]Ga-labelled radiopharmaceuticals-FAP-inhibitors (FAPI)-have shown potential in PET imaging for staging, restaging, and radiation treatment planning in various cancers. High heterogeneity was observed in lesion-based analysis, while promising results were seen in patient-based analysis, particularly for primary lesions and distant metastases.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Nalan Alan-Selcuk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Frederik L. Giesel et al.
Summary: The study aimed to compare Ga-68-FAPI and F-18-FDG in organ biodistribution and tumor uptake in PET/CT, showing that Ga-68-FAPI has lower uptake in most normal tissues compared to F-18-FDG, resulting in significantly higher TBRs at some sites for Ga-68-FAPI.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Katharina Dendl et al.
Summary: Ga-68-FAPI-PET/CT demonstrates high tracer uptake for staging and follow-up of gynecological tumors, with sharp contrasts in primary and metastatic lesions and higher TBRs than F-18-FDG-PET/CT. The presence or absence of the menstrual cycle seems to correlate with FAPI accumulation in the normal endometrium and breast.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ertan Sahin et al.
Summary: This study compared the diagnostic performance of PET/CT using Ga-68-DOTA-FAPI and (18)FDG in detecting liver metastases in patients with GIS cancers. The results showed that Ga-68-DOTA-FAPI-PET/CT was superior to (18)FDG-PET/CT in detecting liver metastases, with significant differences in lesion-based comparisons and semi-quantitative values.
EUROPEAN JOURNAL OF RADIOLOGY
(2021)
Article
Oncology
Junhao Wu et al.
Summary: This retrospective analysis compared the diagnostic efficacy of [Ga-68]Ga-DOTA-FAPI-04 and [F-18]FDG PET/CT in detecting bone metastases in cancer patients. Results showed that [Ga-68]Ga-DOTA-FAPI-04 PET/CT was more sensitive in diagnosing bone metastases compared to [F-18]FDG PET/CT, with higher tracer uptake levels, but also presented a higher rate of false-positive lesions.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Hao Wang et al.
Summary: Ga-68-FAPI-04 PET/CT is more sensitive than F-18-FDG PET/CT in detecting HCC lesions, and Ga-68-FAPI-04 uptake is mainly correlated with tumor size.
FRONTIERS IN ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Annette Altmann et al.
Summary: Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and plays a role in cancer progression and prognosis. FAPI PET/CT imaging, as a promising approach for tumor diagnosis and treatment, offers advantages over conventional F-18-FDG PET/CT in terms of sensitivity and accuracy.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Rheumatology
Christina Bergmann et al.
Summary: This study demonstrates that quantification of fibroblast activation using Ga-68-FAPI-04 PET-CT is associated with disease activity and progression in systemic sclerosis-associated ILD. Increased uptake of Ga-68-FAPI-04 is correlated with extensive disease and previous ILD progression in patients with systemic sclerosis, suggesting its potential in improving risk assessment of ILD.
LANCET RHEUMATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wei Guo et al.
Summary: The study evaluated the potential utility of [Ga-68]Ga-FAPI-04 PET/CT for diagnosing primary and metastatic liver lesions in patients with liver cancer and compared it with other imaging modalities. The findings suggest that [Ga-68]Ga-FAPI-04 PET/CT is comparable to CE-CT and liver MRI in identifying primary liver tumors and metastatic lesions. Additionally, [Ga-68]Ga-FAPI-04 PET/CT outperformed [F-18]-FDG PET/CT in detecting liver lesions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Haojun Chen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2020)
Article
Rheumatology
Christian Schmidkonz et al.
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Manuel Roehrich et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Shozo Okamoto et al.
JOURNAL OF NUCLEAR MEDICINE
(2017)
